Basket | Login | Register

 
 
 
 

Current projects

Our work

All EU-funded or sponsored projects that Alzheimer Europe is currently involved in are listed here. News about these projects, can be found here.

For information about previous projects, please refer to our Annual Reports, which can be found here.

For information on Alzheimer Europe's own projects (e.g. annual publications), please refer to our annual Work Plan here.

EPAD (2015-2020)

The European Prevention of Alzheimer’s dementia (EPAD) initiative is a collaborative research effort to improve the chance of successfully preventing Alzheimer’s dementia and to better understand early aspects of Alzheimer’s disease before dementia develops. The goal of the initiative is the prevention of dementia in people with evidence of the disease (such as biomarker abnormalities) who still may have little or no complaints or clinical symptoms. The programme is part of the Innovative Medicines Initiative, a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.

The EPAD project has received support from the Innovative Medicines Initiative Joint Undertaking
under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

www.ep-ad.org

INDUCT (2016-2019)

INDUCT (Interdisciplinary Network for Dementia Utilising Current Technology) is a four year project under the Marie Sklodowska-Curie Actions Programme. The main aim of INDUCT is to develop a premier quality multi-disciplinary, multi-professional and intersectorial education and training research framework for Europe aimed at improving technology and care for people with dementia, and to use the coherent themes and interrelated Early Stage Researchers ESRs within INDUCT to provide the evidence to show how technology can improve the lives of people with dementia.

www.dementiainduct.eu

MinD (2016-2019)

MinD (Designing for People with Dementia) is a four year project under the Marie Sklodowska-Curie Actions Programme. It aims to help people with dementia engage in social contexts to improve psychosocial wellbeing. Design can offer novel ways of complementing existing care approaches to empower people with dementia in everyday social situations. The project partners will use the concept of mindful design to investigate innovative design solutions, in order to enable self-empowerment and confidence building of people living with dementia. There will be two focus areas: a) personal difficulties with social interaction and b) environmental influences on social engagement. In these two contexts, we will study how personal, wearable designs can help mediate perceptions of identity and emotion management; and how environmental aspects can reduce feelings of information overload and instill feelings of self-empowerment and control.

https://designingfordementia.eu

AMYPAD (2016-2021)

The "Amyloid imaging to prevent Alzheimer’s disease" project aims to improve the diagnostic workup of patients suspected to have Alzheimer's disease and their management. The partners aim to improve knowledge of the natural history of AD in a pre-symptomatic stage, in order to better select patients for trials. In addition, they will monitor changes in beta amyloid deposition in the brain, in order to quantify the impact of novel therapies.

The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. The Joint Undertaking receives support from the European Union’s Horizon2020 research and innovation programme and EFPIA.

www.amypad.eu

DEM 2 - 2nd European Joint Action on Dementia (2016-2019)

The aim of the 2nd European Joint Action on Dementia, known as Dementia Two or DEM 2, is to promote the implementation in EU Member States of coordinated actions to improve the situation of people living with dementia and their carers. These actions were identified by ALCOVE, the first European Joint Action on Alzheimer Cooperative Valuation in Europe, whose partners built a wealth of evidence and knowledge to support Member States in developing their dementia policies and operational capacity. DEM 2 will focus on four key areas for action: diagnosis and post diagnostic support, crisis and care coordination, residential care and dementia-friendly communities.

www.actondementia.eu

MOPEAD (2016-2019)

This 33-month project aims to deliver a step-change in Alzheimer’s disease (AD) patient engagement strategies and a paradigm shift from late-stage diagnosis to early-stage diagnosis. Multiple regional project sites will be established to identify and test models of efficient early identification of mild AD dementia and prodromal AD patients. These models will be compared and contrasted to identify ways to improve early detection and diagnosis of AD. The findings will enable models of patient access to be established and used in the broader AD community. The four patient engagement models which will be tested in five countries (Germany, Netherlands, Slovenia, Spain and Sweden) include assessment based on AD citizen science (online), Open House Initiatives, Primary care and diabetologists’ offices.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No 115985. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations.

www.mopead.eu

Socatel (2017-2020)

H2020 project SoCaTel aims to improve the accessibility, responsiveness, efficiency, transparency and transferability of social and care services by developing a multi-stakeholder platform for the co-creation, and later deployment, of long-term care services.

https://www.socatel.eu/

PRODEMOS (2018-2023)

The PRODEMOS (Prevention of Dementia using Mobile phone Applications) kicked off in January 2018 and will run for five years. This project aims to make an evidence-based dementia prevention strategy using mobile Health accessible to those at increased risk of dementia who are usually not reached by preventive medicine. From a global perspective, the project will target socio-economically deprived populations in the EU and a population at risk of dementia in China. The final aim is to implement this flexible, fully adaptable mHealth platform in a culturally appropriate form in a range of health care settings across the globe. The PRODEMOS project is led by Eric Moll van Charante and Edo Richard (Academish Medisch Centrum bij de Universiteit van Amsterdam).

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779238.

www.prodemos-project.eu/

PARADIGM (2018-2020)

PARADIGM - Patients Active in Research and Dialogues for an Improved Generation of Medicines - is an IMI-funded European project with a mission to provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the “return on the engagement” for all players. The objective is to develop much needed processes and tools for three key decision-making points: research priority setting, design of clinical trials and early dialogue. Building on advances at international level, PARADIGM will integrate the needs, perspectives and expectations of all actors (including vulnerable populations) involved and will also produce a set of metrics to measure the impact of patient engagement. PARADIGM began on 1 March 2018, for 30 months. Alzheimer Europe is a partner and is involved in all work packages of this project.

The PARADIGM project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777450.

http://imi-paradigm.eu/

AD Detect and Prevent (2018-2020)

The Alzheimer’s Disease Detect and Prevent project(ADDP) arrives on the scene at an exciting time for brain health research. In keeping with recent changes in the conceptualisation of and terminology related to Alzheimer’s disease (AD), ADDP is pursuing the ambitious aim of developing a digital tool to improve the detection of AD prior to the possible onset of AD dementia and combining this with programmes for reducing lifestyle risk factors related to developing AD dementia.

The project officially started on 1 November 2018 and is a 2-year project. It has a budget of EUR 3.5 million, distributed across 6 partners, with Danish digital therapeutics company Brain+ leading the consortium. Alzheimer Europe is a partner in this project and is contributing towards the communication and the involvement activities. The latter, is being accomplished by means of a Patient and Public Involvement (PPI) approach.

This project is funded by the European Union’s Horizon 2020 research and innovation programme – Fast Track to Innovation (FTI), grant agreement 820636.

https://www.addp.eu/

Virtual Brain Cloud (2018-2022)

The VirtualBrainCloud project will develop and validate a decision support system that provides access to high quality multi-disciplinary data for clinical practice. The result will be a cloud-based brain simulation platform to support personalised diagnostics and treatments for neurodegenerative diseases (NDD). The resulting software is tailored to the individual, and bridges multiple scales to identify key mechanisms that predict NDD progression. The interdisciplinary VirtualBrainCloud consortium will also develop robust solutions for legal and ethical matters by interacting with the HumanBrainProject, Alzheimer Europe and ELIXIR, an organization that manages and safeguards EU research data. The project started in December 2018 and will conclude at the end of 2022.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 826421.

https://virtualbraincloud-2020.eu

SPAN+: Empowering people with dementia (2018-2022)

Empowerment is important for people with dementia in order to remain engaged with significant others, and to remain involved in society and the decision-making process regarding their care and support. Unfortunately, at present, effective empowerment interventions for people with dementia appear to be scarce, both in the Netherlands and internationally. This Dutch project aims to develop an effective empowerment intervention, which is applicable for people with dementia at home as well as in care homes. Together with input of persons with dementia and carers, the project is looking at the effective and useful elements of existing empowerment interventions and to adapt an existing empowerment intervention for people with young-onset dementia (www.spankrachtbijdementie.nl - only in Dutch), to suit the needs of older people with dementia. They are integrating information from: a European survey, carried out in collaboration with Alzheimer Europe; focus-group meetings with people with dementia, family caregivers and health care professionals; and a literature review on empowerment in people with dementia.  

This study is funded by the programme Memorabel of ZonMw and Deltaplan Dementie of Alzheimer Nederland.

https://www.ukonnetwerk.nl/spanplus/en

NEURONET (2019-2022)

The NEURONET initiative (Efficiently Networking European Neurodegeneration Research) is a three-year coordination and support action that began in March 2019. Its aim is set up an efficient platform to boost synergy and collaboration across the Innovative Medicines Initiative (IMI) projects of the Neurodegenerative Disorders (ND) portfolio, assisting in identifying gaps, multiplying its impact, enhancing its visibility and facilitating dovetailing with related initiatives in Europe and worldwide.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821513. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.

http://www.imi-neuronet.org/

RADAR-AD (2019-2022)

RADAR-AD is a collaborative research initiative that explores the potential of mobile and digital technologies to improve the assessment of Alzheimer’s disease (AD).  The AD terminology in the RADAR-AD project reflects the recent conceptualisation of AD as covering the full spectrum of the disease, including both pre-dementia (preclinical and prodromal AD) and dementia phases (mild to severe AD dementia).

RADAR-AD builds on the knowledge and experience gained in a sister project called RADAR-CNS (Remote Assessment of Disease and Relapse – Central Nervous System), which was launched in 2016 and is exploring remote monitoring in people living with multiple sclerosis, epilepsy and depression.

The RADAR-AD project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 806999.

https://www.radar-ad.org/

DISTINCT (2019-2023)

DISTINCT stands for “dementia: intersectorial strategy for training and innovation network for current technology”. The main aim of DISTINCT is to develop a premier quality multi-disciplinary, multi-professional and intersectorial education and training research framework for Europe. The unique academic and non-academic collaborative partnership of DISTINCT comprises of 13 world leading research organisations across 8 European countries, 9 partners who include Alzheimer Europe, Alzheimer Disease International, the World Federation of Occupational Therapists and 3 small or medium-sized enterprises for technology and dementia care. The University of Nottingham (United Kingdom) manages the DISTINCT programme. DISTINCT is funded by the Marie Skłodowska-Curie Innovative Training Networks (MSC-ITN) under the European Commission's Horizon 2020 programme.

Further information about the project, including details of the students and their projects, can be found at: www.dementiadistinct.com

MIRIADE (2019 – 2023)

MIRIADE (Multi‐omics Interdisciplinary Research Integration to Address DEmentia diagnosis) is a four years project under the Marie Sklodowska-Curie Actions Programme. The main aim of MIRIADE is to train a new generation of scientists that become experts in effective development of novel biomarkers for dementia. MIRIADE will integrate existing biomarker datasets available within the consortium and form a ‘’dementia disease map’’. The young scientists will develop novel biomarker assays using innovative technologies, and MIRIADE will generate novel innovation insights to generate a blueprint for an efficient biomarker development workflow. MIRIADE thus helps to improve the availability of useful biomarkers in clinical practice. This enables early and specific diagnosis of dementia types. Moreover, these biomarkers will help the development of treatments for dementia.

https://miriade.eu/

ADAIR (2020-2022)

A growing body of evidence from epidemiological and animal studies shows that exposure to air pollutants can impair the brain.  The ADAIR project therefore aims to provide crucial mechanistic insight about the effects of air pollutants on the brain in humans and discover biomarkers for air pollution and Alzheimer’s disease (AD) risk prediction. ADAIR addresses a major societal challenge with wide health-related, environmental, economic, scientific, social, and political impact. Lowering the incidence of AD attributable to air pollution and contribution to the mitigation of climate change, are closely linked. The ultimate goal is to develop strategies for early identification of people at risk of AD, and to discover novel targets for preventive strategies in AD.

The ADAIR project is funded by the JPND, for a duration of 36 months. It started in January 2020 and will conclude in December 2022.

https://adair-jpnd.eu/

RECOGNISED (2020-2023)

In recent years there is mounting evidence that type 2 diabetes (T2D) is associated with cognitive impairment and dementia, which can be considered as a “new” long-term diabetic co-morbid complication with substantial consequences for patients and their families and a significant impact on healthcare systems. RECOGNISED (Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia) will apply innovative approaches to identify the molecular mechanisms involved in the high prevalence of cognitive impairment and dementia in the T2D population. It will use this knowledge to characterise clinical phenotypes based on retinal functional and structural characteristics and serum biomarkers in order to stratify the risk and severity of cognitive decline.

The RECOGNISED project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847749.

The project started in January 2020 and will conclude in December 2023.

PRIME (2020-2024)

Aberrant insulin signalling has a substantial impact on health and socioeconomic factors through its role in diabetes, metabolic syndrome, and obesity. Altered insulin signalling also appears to be implicated in Alzheimer’s disease and – based on our pilot work - in mental illnesses characterised by compulsivity, especially obsessive-compulsive disorder and autism. The PRIME (Prevention and Remediation of Insulin Multimorbidity in Europe) brings together a multidisciplinary team to (1) extend our understanding of insulin multimorbidity across the lifespan, (2) understand the causal mechanisms linking somatic and mental insulin-related illnesses, (3) develop tools for early diagnosis, improved clinical care, and prevention of insulin-related lifespan multimorbidity.  PRIME aims to bring this new knowledge to society, based on e.g. repurposing medication and lifestyle interventions (diet/exercise monitored by mHealth assessment), identifying and validating novel drug targets, developing and testing candidate biomarkers, and by improving existing medical guidelines and policy. Furthermore, educational approaches to inform clinicians, patients, and the general public will be developed.

The PRIME project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847879.

The project started in January 2020, and will conclude in December 2024.

EUROFINGERS (2020-2023)

There is, as yet, no cure available for dementia and Alzheimer disease (AD). With prevention therefore being identified as a global priority, the EURO-FINGERS consortium will work towards a novel multimodal precision prevention toolbox, based on an existing successful multimodal lifestyle/vascular prevention model, FINGER (Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability) and on a precision prevention and early detection (PPED) approach, adapted from cancer research.

The EURO-FINGERS Toolbox will include the full range of tools needed to start the next generation of AD dementia prevention trials, within the framework of precision medicine. The aim is to deliver targeted and timely interventions to effectively prevent/delay dementia. The Toolbox will also provide a common framework and align main European cohorts in the AD research field, to deliver results easily implementable in Europe.

The project will align multinational cohorts from observational studies and recent landmark multimodal dementia prevention trials, with new unique long-term trial data. The entire continuum from at-risk and preclinical to prodromal disease stages will be covered, with deep comprehensive clinical, functional and biological assessments.

EUROFINGERS (INTER/JPND/19/BM/14012609) is an EU Joint Programme - Neurodegenerative Disease Research (JPND) project and is supported by the Luxembourg national research fund (FNR).

The  project started in January 2020 and will conclude in December 2023. 

 

 
 

Last Updated: Wednesday 09 September 2020

 
 
 

Options